Oncology & Genomics

Watson and Cancer:
Get the Facts

Share this post:

Watson is helping doctors across the globe to find the best cancer treatments and is at work in more than 50 hospitals in 13 countries across five continents. When you consider our Watson for Oncology’s global adoption, initial concordance studies, thousands of patient cases processed and our patient and physician testimonials, there is no question that we are having a positive impact on oncology care around the world.

Learn more below about Watson for Oncology below from patients, physicians, and researchers and the data points that accentuate the impact of the technology globally.

Watson for Oncology facts

  • Watson for Oncology is among the first AI-driven oncology clinical decision support systems, which is being used around the world to help clinicians advance cancer care.
  • Watson for Oncology is scaling rapidly. To date, it is being used by more than 50 hospitals around the world.
  • Watson for Oncology was trained by New York’s Memorial Sloan Kettering Cancer Center (MSK), one of world’s the leading cancer centers.
  • Watson for Oncology derives hundreds of attributes from a patient’s electronic health record, including doctors’ notes and lab reports, and analyzes them using Natural Language Processing (NLP) technology. Then, it provides clinicians with confidence-ranked treatment options and supporting evidence to help them make treatment decisions for their patients.
  • Doctors and patients report Watson for Oncology is helping to inform doctors’ treatment decisions and boosting patient confidence in doctor recommendations.
  • Watson for Oncology is now available to assist clinicians on breast, lung, colon, rectal, gastric, ovarian, cervical and prostate cancers.
  • Watson’s suite of oncology offerings have already touched 14,000 people across the globe.
  • Watson for Oncology can integrate with multiple users’ EHR systems.
  • Data about Watson in health is made widely available via presentations at technical, scientific and medical meetings and in peer-review publications.

Client insights

Jupiter Medical

“It’s really an amazing tool. It gives our multidisciplinary team of doctors, as well as our patients, great confidence that we have identified the most up-to-date treatment regimen available.” –Dr. Abraham Schwarzberg, Chief of Oncology at Jupiter Medical Center

Hackensack Meridian Health with Cota

“Hackensack Meridian Health is excited to expand our existing partnership with Cota by incorporating the deep insights Watson for Oncology has to offer,” said Robert Garrett, co-CEO of Hackensack Meridian Health. “We pride ourselves on our ability to provide patients with cutting edge care and this pilot will help us achieve that mission while also reducing the total cost of care and getting us closer to value-based care trends, like bundled payments. Our collaboration with IBM and Cota will allow us to do just that, while furthering our commitment to innovation and stretching the limits of health care.”

Bumrungrad International Hospitals

“Watson for Oncology is one example of the key technologies that will help clinicians harness the increasing amounts of data that is becoming available as both medicine and treatment become more personalized for each individual patient,” said Nan Chen, the Senior Director of Research & Development and Clinical Data at Bumrungrad International Hospital. “As we treat more than half a million from over 190 countries each year, these technologies are increasingly important to provide the level of care that our patients have come to expect.”

Baheal Group

“Oncologists in China have very little time to spend with each of their patients, and by deploying Watson for Oncology across our network, we aim to give our doctors more time to focus on the best decisions they can make for their patients,” said Gang Fu, Chairman, Baheal Pharmaceutical Group. “Watson for Oncology will complement the robust digital health program that Baheal has already implemented in an effort to improve efficiency and quality across China’s healthcare system.”

Manipal Hospitals

“The introduction of Watson for Oncology will be a game changer for cancer patients across the country. With Watson, Manipal oncologists can make informed treatment decisions for patients based on insights derived from the individuals’ unique health status, the latest medical research and other relevant data,” said Dr. Ajay Bakshi, MD & CEO, Manipal Hospitals.

Gachon University Gil Medical Center

Uhn Lee, Director of AI-based Precision Medicine at Gachon University Gil Medical Center, said, “Our clinical staff always aims to provide effective, personalized, and evidence-based care to every patient we treat, yet it can be difficult to keep up with the latest scientific studies from around the world. With its ability to analyze large volumes of disparate data and synthesize that data into actionable information, Watson for Oncology will help our clinicians deliver world-class, data-driven care to their patients.”

Konyang University Hospital

“Patients outside of the Seoul metropolitan area have had to visit hospitals in the capital city for second opinions. Watson for Oncology will eliminate such inconveniences,” Konyang University Hospital Director Choi Won-jun said in a statement. “Adding an AI-based medical system to the hospital’s talented joint cancer treatment team, we expect to be able to provide the best medical services for cancer patients.”

Grupo Ángeles Servicios de Salud

“Ángeles is the biggest private healthcare institution in Mexico. The introduction of Watson for Oncology will be a game changer for cancer patients in the whole country” said Florentino Bernardo Pérez, CIO Grupo Empresarial Ángeles. “With Watson, our team of oncologists can make informed treatment decisions for patients based on insights derived from the individuals’ unique health status, medical research and other relevant data.”

Icon Group

Cathie Reid, Co-Founder and Digital Advisor for Icon Group said, “The Icon Group and IBM Watson Health partnership complements our growing portfolio of digital health services, and will help our physicians understand the subtleties of each patient’s illness by combining their expertise with the increasing amounts of oncology literature available globally. Investment in this technology will allow us to further support our oncology clinicians across Australia in their treatment decisions.”

Hangzhou CognitiveCare

“Hangzhou CognitiveCare is eager to bring IBM’s Watson for Oncology to reach every oncologist in China we possibly can,” said Zhen Tu, CEO of Hangzhou Cognitive Care. “Watson has the power to transform how doctors battle cancer in China and around the world, providing physicians with insights regarding treatment options that help them customize therapeutic recommendations specific to each individual, based on a patient’s specific needs.”

Patient experience

Hospital experience

Research experience

Data and evidence

Watson for Oncology achieved a concordance rate of 96% for lung, 81% for colon and 93% for rectal cancer cases compared to recommendations from the multi-disciplinary tumor board in a study at Manipal Comprehensive Cancer Centre in Bangalore, India.

Watson for Oncology achieved a concordance rate of 83% for multiple cancer types compared to recommendations from oncologists in a study at Bumrungrad International Hospital, a multispecialty hospital in Bangkok, Thailand.

Watson for Oncology found useful in Mexico. In a qualitative study, oncologists in Mexico found Watson for Oncology to be useful to help them identify potential treatment options for their patients, particularly in clinics that lack subspecialist expertise, and for training medical students and residents.

SABCS 2016: IBM Watson for Oncology Platform Shows High Degree of Concordance with Physician Recommendations.

Watson for Oncology achieved a concordance rate of 73% for high-risk colon cancer cases when compared to the tumor board from Gachon University Gil Medical Centre in Incheon, South Korea.

Industry perspectives

Artificial Intelligence is coming of age in healthcare as technology suppliers, like IBM, make progress in the democratization of this technology. The application of AI will be a major disruptor in healthcare and move the industry closer to its goal of value-based health.

Cynthia Burghard, research director IDC Health Insights, Progress Toward the Democratization of Watson for Oncology

Watson for Oncology is fundamentally reshaping how oncologists derive insights that enable the best possible decision making and highest quality patient care.

Nancy Fabozzi, health analyst at Frost & Sullivan

More Oncology & Genomics Stories

Empowering Heroes Means Enabling Humanistic Health Care

Written by Deborah DiSanzo | Cognitive Computing

At IBM Watson Health, our stated goal is "Empowering Heroes, Transforming Health." We help empower heroes by creating technology designed to enhance their abilities to make the essential connections that transform health. ...read more


3 Ways Cognitive Computing Could Aid Value-Based Care

Written by Watson Health | Article, Care Management, Cognitive Computing

In this article, review key areas where cognitive computing could support care management efforts, including providing highly tailored insights about individual patients across an entire population, and helping providers more effectively address social determinants of health. ...read more


Do doctors fear AI? Not the hundreds I work with around the world

Written by Kyu Rhee | Blog Post, Cognitive Computing

Headlines abound about doctors cowering from AI. The reality: not so much. I’m a physician, and don’t think that’s a realistic concern. Rather, I envision a future in which AI-enabled insights help health and medical experts deliver patient-centered, personalized, value-based care. The future is here. For those of us at IBM, we are augmenting experts’ ...read more